EssilorLuxottica : Very little upside potential, so the risk for a correction is significant
Entry price | Target | Stop-loss | Potential |
---|
€165.36 |
€157.48 |
€169.4 |
+4.77% |
---|
The price of shares in EssilorLuxottica is close to a major medium term resistance level around 166.2 EUR. A correction phase over the short term appears to be the logical outcome.
Strengths● The company's profit outlook over the next few years is a strong asset.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● For the past twelve months, EPS forecast has been revised upwards.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
● Analyst opinion has improved significantly over the past four months.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses● With an expected P/E ratio at 38.04 and 32.19 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
● The group usually releases earnings worse than estimated.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.